Why Is Ionis Pharmaceuticals (IONS) Stock Down -20.65% Today?
Key Takeaways
- Ionis Pharmaceuticals shares are plunging roughly 20.65% in premarket trading, falling from a previous close of $84.46 to around $67.02.
- The primary catalyst is the failure of the Phase 3 CARDIO-TTRansform trial for eplontersen, co-developed with AstraZeneca, which missed its primary efficacy endpoint in patients with transthyretin-mediated amyloid cardiomyopathy.
- AstraZeneca shares are also sliding roughly 8-9% in sympathy, reflecting the shared setback for the two companies' cardiovascular franchise.
- The drop marks a sharp reversal after the stock had been trading near its 52-week high, up nearly 97% over the trailing year heading into the announcement.
- Broader biotech sentiment is being tested as investors reassess pipeline risk across RNA-targeted therapeutics following the disappointing data.
- Traders are now watching for detailed trial data at the European Society of Cardiology Congress in August 2026 and any regulatory commentary from the companies.
Opening Summary
Ionis Pharmaceuticals, Inc. (IONS), a commercial-stage biotechnology company specializing in RNA-targeted medicines, is seeing its shares slide sharply in premarket trading on Thursday. The stock is down approximately 20.65%, dropping from Wednesday's close of $84.46 to roughly $67.02. The immediate trigger is disappointing late-stage clinical trial results for eplontersen, a heart disease therapy developed in partnership with AstraZeneca, which failed to meet its primary efficacy goal. The move represents one of the steepest single-session declines for the stock in recent memory and stands in stark contrast to its recent run to near-record highs.
Clinical Trial Failure Drives the Selloff
The core catalyst behind the decline is the outcome of the Phase 3 CARDIO-TTRansform study, which evaluated eplontersen in patients with wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy. The trial, which enrolled 1,432 participants across 130 sites in 20 countries, did not demonstrate a statistically significant benefit on the composite endpoint of cardiovascular mortality and recurrent cardiovascular events through Week 140 compared with placebo. A prespecified subgroup analysis did show a nominally significant benefit for patients on eplontersen monotherapy, but no treatment effect was observed among patients already receiving background stabilizer therapy, undercutting the drug's broader commercial case. This missed endpoint directly threatens a key growth pillar for Ionis's cardiovascular pipeline, prompting an immediate and severe repricing of the stock.
AstraZeneca Partnership Adds to Pressure
Because eplontersen, marketed as Wainua, is co-developed and commercialized with AstraZeneca, the setback is weighing on both companies simultaneously. AstraZeneca shares fell roughly 8.8% in London trading and were down about 8% in U.S. premarket action, marking one of its worst sessions since the pandemic-era selloff in March 2020. The shared partnership structure means both companies now face reduced near-term revenue expectations tied to the cardiomyopathy indication, amplifying the market reaction beyond what either company might have experienced independently.
Sector and Sentiment Context
The failed trial is reverberating through the broader biotech and pharmaceutical sector, reinforcing investor caution around binary clinical trial outcomes even for well-established RNA-targeted drug developers. Despite Thursday's plunge, it's worth noting the stock had been trading near its 52-week high of $86.74 heading into the announcement, having gained close to 97% over the past year on the strength of other pipeline successes such as Tryngolza. That prior strength suggests the current move is a sharp, catalyst-specific correction rather than a broader deterioration in the company's commercial business.
Market Context and Trading Activity
Premarket volume in IONS has been notably elevated as investors react to the trial data released ahead of the opening bell. The decline appears isolated to Ionis and its direct partner AstraZeneca rather than reflecting a broader move across major indices, indicating a company- and drug-specific event rather than a macro-driven selloff. The scale of the drop, over 20% in premarket trading, breaks decisively through recent technical support levels the stock had established near its 52-week highs, erasing weeks of gains in a single session.
Trending AI Robots
For traders looking to navigate volatile sessions like this one, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies performing well under current market conditions. Tickeron runs hundreds of AI trading bots across thousands of tickers, but only the strongest performers are surfaced in this trending section at any given time. These bots vary widely by strategy, timeframe, performance metrics, and the specific symbols they trade, giving users a snapshot of which automated approaches are currently outperforming. Investors interested in systematic, data-driven trading tools may find it useful to explore the Trending AI Robots section for ideas on how algorithmic strategies are adapting to sessions featuring sharp, news-driven moves like today's action in Ionis shares.
What Comes Next for IONS
Looking ahead, investors will be watching for the full CARDIO-TTRansform dataset, expected to be presented at the European Society of Cardiology Congress in August 2026, which should clarify the drug's subgroup performance and any path forward for eplontersen in this indication. Analyst commentary and any updated guidance from Ionis or AstraZeneca regarding the cardiomyopathy program will also be closely monitored in the days ahead. Beyond this setback, the company's broader pipeline, including approved therapies like Tryngolza and ongoing programs in rare diseases, remains a factor investors will weigh against the near-term disappointment. As with any single trial readout, uncertainty remains around how regulators, physicians, and the market will ultimately interpret the mixed subgroup results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
IONS in -1.14% downward trend, declining for three consecutive days on October 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IONS declined for three days, in 171 of 272 cases, the price declined further within the following month. The odds of a continued downward trend are 63%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for IONS entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IONS's RSI Indicator exited the oversold zone, 20 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on IONS as a result. In 75 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for IONS just turned positive on October 02, 2026. Looking at past instances where IONS's MACD turned positive, the stock continued to rise in 35 of 51 cases over the following month. The odds of a continued upward trend are 69%.
Following a +1.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where IONS advanced for three days, in 192 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
IONS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IONS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. IONS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.212) is normal, around the industry mean (26.780). IONS's P/E Ratio (555.556) is considerably higher than the industry average of (43.395). Projected Growth (PEG Ratio) (4.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (8.368) is also within normal values, averaging (438.009).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of antisense drugs
Industry Biotechnology
Advertisement